TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TQB-2618’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TQB-2618 overview
TQB-2618 is under development for the treatment of advanced solid tumors relapsed and refractory acute myeloid leukemia, Hodgkin lymphoma (cHL), B lymphocyte non-Hodgkin lymphoma (B-NHL), T lymphocyte non-Hodgkin lymphoma (T-NHL), advanced melanoma, small-cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer, recurrent head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, or laryngeal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, metastatic colorectal cancer and myelodysplastic syndrome. It is a monoclonal antibody. It is administered through Intravenous route. The therapeutic candidate acts by targeting T-cell immunoglobulin mucin domain 3 (TIM-3).
See Also:
Chia Tai Tianqing Pharmaceutical Group overview
Chia Tai Tianqing Pharmaceutical Group (CTTQ) manufactures and commercializes anticancer drugs. The company produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, engineering novel liver, cardiovascular, cancer, mental, anesthesia, urinary, and others. The company operates through its technology and research and development centers in Jiangsu. CTTQ is headquartered in Lianyungang, Nanjing, China.
For a complete picture of TQB-2618’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
